Cannabidiol and Aza-BODIPY Coencapsulation for Photodynamic Therapy Enhancement in Liver Cancer Cells.
Sastiya KampaengsriPrapassara MuangsopaAmorn PangjantukKantapat ChansaenpakRung-Yi LaiParinya NoisaAnyanee KamkaewPublished in: ACS applied bio materials (2024)
Photodynamic therapy (PDT) and cannabidiol (CBD) have been explored for their potential in synergistic cancer treatment. In this study, we employed CBD oil as a lipid phase, encapsulated within AZB-I@Lec-T to create lipid-based nanoparticles. Here, CBD oil does two tasks: it acts as a pyroptosis agent to destroy liver cancer cells and as a lipid phase to dissolve the photosensitizer. It was expected that this system would offer synergistic therapy between CBD and PDT better than a single use of each treatment. With a series of in vitro experiments, the nanoparticles exhibited induced apoptosis in 68% of HepG2 cells treated with AZB-I@Lec-T@CBD and near-infrared (NIR)-light irradiation, reducing expression levels of antioxidant defense system genes. Furthermore, both components worked well in a submicromolar range when combined in our formulation. These results highlight the potential for amplifying primary cellular damage with the combination of PDT and CBD encapsulation, providing a promising therapeutic approach for liver cancer treatment guidelines.
Keyphrases
- photodynamic therapy
- induced apoptosis
- fluorescence imaging
- fatty acid
- oxidative stress
- endoplasmic reticulum stress
- poor prognosis
- signaling pathway
- working memory
- human health
- gene expression
- risk assessment
- binding protein
- transcription factor
- anti inflammatory
- long non coding rna
- living cells
- smoking cessation
- drug release